futibatinib
futibatinib: 8 clinical trials tracked.
futibatinib evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
What is verified about futibatinib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Clinical Trial Registry Records (8)
An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study
Primary endpoint: Number of participants with serious adverse events, treatment-related adverse events, and any AEs leading to treatment discontinuation graded according to NCI-CTCAE v5.0.
Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Primary endpoint: Progression-free survival (PFS)
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.
Primary endpoint: ORR by investigator assessment
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications
Primary endpoint: Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825
A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Primary endpoint: Objective Response Rate (ORR)
A Phase 2 Study of Futibatinib in Patients With Specific FGFR Aberrations
Primary endpoint: Objective Response Rate (ORR) Based on Independent Central Review (IRC) in Cohorts A and B
A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications
Primary endpoint: Objective Response Rate (ORR) - Cohorts 1, 2
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Primary endpoint: Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria